<DOC>
	<DOCNO>NCT02488564</DOCNO>
	<brief_summary>It multicenter , open-label , two stage phase II trial , ass activity , safety potential early predictor response neoadjuvant setting . Patients operable breast cancer ( T1c cytologically N1-2 , cT2-3 , N0-N2 , M0 ) locally advanced breast cancer ( T4a-d , N0-N2 , M0 ) overexpression amplification HER2 ( AJCC 7th edition 2010 ) include study . The primary objective evaluate pathological complete response rate ( pCR ) . The secondary objective : - evaluate clinical response rate ( RR ) . - evaluate feasibility systemic tolerance , particular attention cardiac toxicity . - evaluate conservative surgery rate . Total duration trial 36 month ; plan treatment 6 cycle chemotherapy . At every cycle ( every 21 day ) administer : Day 1 : Liposome-encapsulated doxorubicin , 50 mg/m2 IV 1 hour infusion ; Day 2 9 : Docetaxel , 30 mg/m2 IV 1 hour infusion ; Day 2 , 9 16 : Trastuzumab 4 mg/kg first infusion load dose , 2 mg/kg/week subsequent injection . Day -13 0 : Metformin administer single agent . From day -13 day -11 , Metformin 1000 mg administer day ; day -10 Metformin 1000 mg administer twice day continuously end study treatment .</brief_summary>
	<brief_title>A Study Liposomal Doxorubicin + Docetaxel + Trastuzumab + Metformin Operable Locally Advanced HER2 Positive Breast Cancer</brief_title>
	<detailed_description>Multi-center , open-label phase II trial ass activity chemotherapy scheme evaluate pathologic complete response rate ( pCR ) . Planned treatment 6 cycle chemotherapy . At every cycle ( every 21 day ) administer : Day 1 : Liposome-encapsulated doxorubicin , 50 mg/m2 IV 1 hour infusion ; Day 2 9 : Docetaxel , 30 mg/m2 IV 1 hour infusion ; Day 2 , 9 16 : Trastuzumab 4 mg/kg first infusion load dose , 2 mg/kg/week subsequent injection Day -13 0 : Metformin administer single agent . From day -13 day -11 , Metformin 1000 mg administer day ; day -10 Metformin 1000 mg administer twice day continuously end study treatment . Total duration trial : 36 month Enrollment period : 24 month Treatment : maximum 6 cycle ( 5 month ) per patient Follow-up recurrence : every six month 5 year , year 10 year surgery.It 's necessary recruit 46 patient clinical objective evaluation .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patients must histologically confirm breast cancer HER2 overexpressing cancer Patients operable breast cancer ( T1c cytologically N12 , cT23 , N0N2 , M0 ) locally advanced breast cancer ( T4ad , N0N2 , M0 ) ( AJCC 7th edition 2010 ) . No prior therapy breast cancer Both sex , age ≥ 18 year &lt; 75 year Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Life expectancy &gt; 3 month Neutrophil count ≥ 2 x 109/ L , leukocytes count ≥ 3 x 109/ L platelet count ≥ 100 x 109/ L Total bilirubin ≤ 1 uppernormal limit ( UNL ) Institutional normal value alanine aminotransferase ( ASAT ( GOT ) and/or alanine aminotransferase ALAT ( GPT ) ≤ 2.5 UNL , alkaline phosphatase ≤ 5 UNL . Patients ASAT and/or ALAT &gt; 1.5 UNL alkaline phosphatase &gt; 2.5 UNL n't eligible trial . Creatinine ≤ 1.5 mg/dL Left ventricular ejection fraction ( LVEF ) ≥ 50 % ( evaluate echocardiogram multiple gated acquisition scan ( MUGA ) scan one method must employ patient ) Written informed consent Homa Index calculate use Matthews'formula EXCLUSION CRITERIA : Prior chemotherapy radiotherapy breast cancer . History prior malignancy last 10 year ( nonmelanoma skin cancer excise cervical carcinoma situ ) . Other serious illness medical condition Congestive heart failure angina pectoris even medically control . Previous history myocardial infarction , uncontrolled high risk hypertension arrhythmia History significant neurologic psychiatric disorder include dementia seizure Active infection Concurrent treatment experimental drug . Participation another clinical trial investigational agent within 30 day prior study screen . Geographic inaccessibility treatment followup Pregnant lactate woman Diabetesinsulin dependant noninsulin dependant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HER-2 Positive Breast Cancer</keyword>
	<keyword>operable breast cancer</keyword>
	<keyword>locally advanced breast cancer</keyword>
	<keyword>prior therapy</keyword>
	<keyword>pCR</keyword>
</DOC>